1. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. (31st October 2017) Authors: Kalin, Alexander; Medina-Paraiso, Elvia; Ishizaki, Kaoru; Kim, Alex; Zhang, Yannong; Saita, Takanori; Wasaki, Masahiko Journal: Amyotrophic lateral sclerosis and frontotemporal degeneration Issue: Volume 18(2017)Supplement 1 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Issue 2 (28th December 2022) Authors: Genge, Angela; Pattee, Gary L.; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Bidani, Sachin; Hirai, Manabu; Sakata, Takeshi; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E. Journal: Muscle & nerve Issue: Volume 67:Issue 2(2023) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗